Last reviewed · How we verify

NCT05773599

Midwifery Students and Laughter Yoga

Completed NA Last updated 29 December 2023
What this trial tests

NA trial testing laughter yoga in Laughter Yoga in 77 participants. Completed in 27 January 2023.

Timeline
9 January 2023
Primary endpoint
13 January 2023
27 January 2023

Quick facts

Lead sponsorAtaturk University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment77
Start date9 January 2023
Primary completion13 January 2023
Estimated completion27 January 2023
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Ataturk University

Who can join

Eligibility, female only, with Laughter Yoga or Midwifery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

No study was found as a result of the literature review. It is thought that laughter yoga will affect the life satisfaction and sleep quality of individuals due to reasons such as increasing oxygen saturation in the blood, strengthening mental functions, providing mental well-being and reducing stress. stress and mental fatigue are thought to affect life satisfaction and sleep quality, so it was planned to evaluate the effect of laughter yoga on life satisfaction and sleep quality.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of laughter yoga

Trials testing the same drug.

Other recruiting trials for Laughter Yoga

Currently open trials in the same condition.

Other Ataturk University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05773599.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing